ADMA Biologics (ADMA) PT Lowered to $18 at Canaccord
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ADMA Hot Sheet
Price: $11.02 -0.36%
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 13
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 13
Join SI Premium – FREE
Canaccord analyst Gary Nachmann lowered the price target on ADMA Biologics (NASDAQ: ADMA) to $18.00 (from $21.00) while maintaining a Buy rating.
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Tower Semiconductor (TSEM) PT Lowered to $235 at Stifel
- DigitalOcean (DOCN) PT Lowered to $130 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
